Browsing by Author "Berhanu, Mulugeta"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    An innovative method for accelerating vaccine formulation development and manufacturing process: Using prefabricated vaccine base (standardized mixtures of vaccine excipients)
    (2021-08-05) Berhanu, Mulugeta
    Vaccine base can be defined as a standardized mixtures of vaccine excipients such as adjuvants emulsifier, preservatives, stabilizer, surfactant, buffers and etc. Vaccine bases are substances to which antigen (s) is/are added to form the final product (vaccine) which can provide protection against infectious disease. Prefabricated vaccine base can be used to develop vaccines in an easy and fast way. With vaccine base we do not need to formulate vaccines from scratch. Just we incorporate antigen of interest in vaccine base and vaccine is completed. Thus, premade vaccine base can be used to accelerate vaccine formulation development during global pandemics and epidemics. Using prefabricated vaccine base for vaccine development against various infectious diseases is an innovative method for accelerating deployment of existing and novel vaccines. Prefabrication of vaccine base is a new preparedness strategy for the future pandemics.
  • Thumbnail Image
    Item
    Vaccine containing immunologic adjuvants with a wide range of activity to provide protection against COVID-19
    (2021-07-30) Berhanu, Mulugeta
    COVID-19 is a devastating viral disease which can be prevented by vaccination. Immunologic adjuvants are key to develop an effective vaccines against infectious diseases in human and non-human primates. Vaccines containing an appropriate adjuvants are crucial for the prevention of various infectious diseases which are the biggest threats to human and animal health. This paper proposes a wide spectrum immunologic adjuvant for vaccine development against COVID-19 which is the current global problem. It has been reported that a wide range of immune cells are involved in the body’s response to SARS CoV2 infection. Therefore, vaccine with a wide-spectrum immunologic adjuvant can be used to provide protection against COVID-19. Lack of adjuvants that can induce the required immune responses is a serious impediment to vaccine development against this devastating virus. The approved adjuvants such as aluminum salts and MF59 exhibit a narrow range of activity. In an attempt to solve this problem, it is crucial to develop new adjuvants which can trigger a wide range of immune cells.